ArticleAnalytical and bioanalytical chemistry2026
Rapid LC-MS/MS-based quantitative serum tryptophan metabolomics platform identifies and monitors novel biomarkers for diabetic kidney disease.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease worldwide. Conventional diagnostic tools lack sufficient sensitivity, necessitating novel biomarkers and reliable analytical platforms to improve DKD management. In this study, a serum tryptophan (TRP) metabolomics platform based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed. After analytical optimization and validation, this platform was applied to a hospital-based case-control study (n = 200) for DKD. Associations between TRP metabolites and DKD risk were investigated via multivariable logistic regression. Metabolites demonstrating independent associations underwent diagnostic evaluation using receiver operating characteristic analysis with bootstrap internal validation. This LC-MS/MS platform enabled rapid quantification for TRP and 18 related metabolites within 6 min with low limits of detection, satisfactory recoveries, and acceptable matrix effects, meeting stringent analytical criteria suitable for clinical application. Seven TRP metabolites were significantly associated with DKD after covariate adjustment: 3-hydroxykynurenine (3-HK), 5-hydroxyindole acetic acid, indole-3-acetamide, and indole exhibited positive associations, while 3-hydroxyanthranilic acid, 5-hydroxytryptophan, and xanthurenic acid (XA) showed inverse associations. Individual metabolites demonstrated promising diagnostic performance (AUCs 0.762-0.896, sensitivities 65-80%, specificities 63-91%), except indole (AUC 0.683, sensitivity 51%, specificity 85%). Critically, the biomarker panel combining 3-HK and XA achieved exceptional diagnostic accuracy (AUC 0.970, sensitivity 92%, specificity 98%) for DKD. Bootstrap internal validation confirmed the stability of these findings. This study provided an LC-MS/MS-based platform for serum TRP metabolomics and identified a biomarker panel with exceptional diagnostic accuracy for DKD, offering significant potential as a clinically feasible tool for improving the diagnosis and management of DKD.
Indexed as
Identifiers
41219529What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.